Dimension Therapeutics Inc (DMTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Dimension Therapeutics Inc (DMTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH501589D
  • |
  • Pages: 52
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Dimension Therapeutics Inc (Dimension Therapeutics) is a developer of therapeutic products for the treatment of rare diseases associated with liver and genetic mutations. The company develops its product pipeline based on its mammalian adeno-associated virus gene delivery technology. Its products under development are intended for the treatment of inherited metabolic diseases including ornithine transcarbamylase deficiency, glycogen storage disease type Ia (GSDIa), citrullinemia type 1, PKU, wilson disease and hemophilia. The company also develops and commercialize product candidates for the treatment of hemophilia A. Dimension Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Dimension Therapeutics Inc (DMTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Dimension Therapeutics Raises USD65 Million in Series B Financing 11

Dimension Therapeutics Raises USD30 Million in Venture Financing 12

Dimension Therapeutics Raises USD5 Million in Series A Financing 13

Partnerships 14

Aptuit Enters into Agreement with Dimension Therapeutics 14

Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 15

Licensing Agreements 15

Bayer HealthCare Enters into Licensing Agreement with Dimension Therapeutics for Hemophilia A 15

Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 16

ReGenX Biosciences Amends Licensing Agreement with Dimension Therapeutics 17

ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 18

Equity Offering 19

Dimension Therapeutics Plans to Raise up to USD35 Million in Public Offering of Shares 19

Dimension Therapeutics Prices IPO for USD71.5 Million 20

Dimension Therapeutics Inc-Key Competitors 22

Key Employees 23

Locations And Subsidiaries 24

Head Office 24

Other Locations & Subsidiaries 24

Recent Developments 25

Financial Announcements 25

May 10, 2017: Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 25

Mar 09, 2017: Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing 27

Nov 10, 2016: Dimension Therapeutics Reports Recent Corporate Progress and Third Quarter 2016 Financial Results 29

Aug 11, 2016: Dimension Therapeutics Reports Recent Corporate Progress and Second Quarter 2016 Financial Results 30

May 12, 2016: Dimension Therapeutics Reports Recent Corporate Progress And First Quarter 2016 Financial Results 31

Mar 24, 2016: Dimension Therapeutics Reports Recent Corporate Progress and Full Year 2015 Financial Results 33

Corporate Communications 34

Jul 24, 2017: Dimension Therapeutics Announces Management Change 34

Feb 07, 2017: Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors 35

Product News 36

Jun 22, 2016: Dimension Therapeutics Announces Recombinant DNA Advisory Committee's Unanimous Approval of Phase 1/2 Study Protocol for DTX301, Lead Inherited Metabolic Disease (IMD) Product Candidate to Treat OTC Deficiency 36

May 27, 2016: Dimension Therapeutics Announces Presentations At The 8th European Conference On Rare Diseases & Orphan Products (ECRD) 37

Apr 24, 2017: Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy Annual Meeting 38

Product Approvals 40

Dec 13, 2016: Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency 40

Mar 17, 2016: Dimension Therapeutics Receives Positive Opinion for European Orphan Drug Designation for DTX301 for the Treatment of Ornithine Transcarbamylase Deficiency 41

Jan 06, 2016: Dimension Therapeutics Announces Orphan Drug Designation of DTX301 for the Treatment of Ornithine Transcarbamylase Deficiency 42

Clinical Trials 43

May 19, 2016: Dimension Therapeutics Announces Presentation on DTX-101 at the Upcoming 21st Congress of the European Hematology Association 43

May 19, 2016: Dimension Therapeutics Announces Presentation on DTX201 at the Upcoming 21st Congress of the European Hematology Association 44

May 07, 2016: Dimension Therapeutics Announces Preclinical Data From Bayer-Partnered Hemophilia A Program At American Society For Gene And Cell Therapy (ASGCT) Annual Meeting 45

May 05, 2016: Dimension Therapeutics Announces Preclinical Data Supporting Ongoing DTX101 Phase 1/2 Clinical Trial At American Society For Gene And Cell Therapy Annual Meeting 46

Apr 18, 2016: Dimension Therapeutics announces preclinical data on hemophilia A program at upcoming American Society For Gene And Cell Therapy (ASGCT) annual meeting 47

Apr 18, 2016: Dimension Therapeutics announces preclinical data on hemophilia B program at upcoming American Society For Gene And Cell Therapy (ASGCT) annual meeting 49

Other Significant Developments 51

Jun 27, 2017: Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities 51

Appendix 52

Methodology 52

About GlobalData 52

Contact Us 52

Disclaimer 52

List of Figures

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Dimension Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Dimension Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Dimension Therapeutics Raises USD65 Million in Series B Financing 11

Dimension Therapeutics Raises USD30 Million in Venture Financing 12

Dimension Therapeutics Raises USD5 Million in Series A Financing 13

Aptuit Enters into Agreement with Dimension Therapeutics 14

Dimension Therapeutics Amends Research Agreement with University of Pennsylvania 15

Bayer HealthCare Enters into Licensing Agreement with Dimension Therapeutics for Hemophilia A 15

Dimension Therapeutics Enters into Licensing Agreement with Perelman School of Medicine at the University of Pennsylvania 16

ReGenX Biosciences Amends Licensing Agreement with Dimension Therapeutics 17

ReGenX Biosciences Amends Licensing Agreement With Dimension Therapeutics 18

Dimension Therapeutics Plans to Raise up to USD35 Million in Public Offering of Shares 19

Dimension Therapeutics Prices IPO for USD71.5 Million 20

Dimension Therapeutics Inc, Key Competitors 22

Dimension Therapeutics Inc, Key Employees 23

Dimension Therapeutics Inc, Subsidiaries 24

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Dimension Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com